Gain Therapeutics (GANX)
(Delayed Data from NSDQ)
$1.06 USD
-0.02 (-1.85%)
Updated Aug 1, 2024 04:00 PM ET
After-Market: $1.05 -0.01 (-0.94%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum F VGM
Income Statements
Fiscal Year end for Gain Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 22 | 18 | 14 | 4 | 2 |
Income After Depreciation & Amortization | -22 | -18 | -14 | -3 | -2 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -22 | -18 | -14 | -4 | -2 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -22 | -18 | -14 | -4 | -2 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -22 | -18 | -14 | -4 | -2 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -22 | -18 | -14 | -3 | -2 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -22 | -18 | -14 | -3 | -2 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 13.01 | 11.88 | 10.17 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.71 | -1.48 | -1.37 | NA | NA |
Diluted Net EPS (GAAP) | -1.71 | -1.48 | -1.37 | -1.17 | NA |
Fiscal Year end for Gain Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 4.38 | 4.40 | 4.89 | 7.73 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -4.38 | -4.40 | -4.89 | -7.73 |
Non-Operating Income | NA | 0.38 | -0.30 | 0.19 | 0.07 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -3.99 | -4.71 | -4.70 | -7.66 |
Income Taxes | NA | 0.02 | 0.01 | 0.02 | 0.03 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -4.01 | -4.72 | -4.72 | -7.69 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -4.01 | -4.72 | -4.72 | -7.69 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 17.98 | 16.29 | 12.70 | 12.39 |
Diluted EPS Before Non-Recurring Items | NA | -0.22 | -0.29 | -0.37 | -0.62 |
Diluted Net EPS (GAAP) | NA | -0.22 | -0.29 | -0.37 | -0.62 |